Kiora Pharmaceuticals financials
$2.60−2.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $16.0M | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $16.0M | $0.00 | $0.00 | — |
| Gross margin | — | 100.0% | — | — | — |
| Operating income | -$12.8M | $4.5M | -$12.6M | -$12.3M | -$14.2M |
| Net income | -$10.8M | $3.6M | -$13.0M | -$13.6M | -$13.8M |
| Net margin | — | 22.4% | — | — | — |
| Diluted EPS | $-2.64 | $0.87 | $-24.25 | $-166.95 | $-514.08 |
| EBITDA | -$8.2M | $6.5M | -$10.6M | -$11.7M | -$10.6M |
| Operating cash flow | -$10.0M | $8.6M | -$9.6M | -$10.4M | -$10.7M |
| Free cash flow | -$10.1M | $8.6M | -$9.6M | -$10.4M | -$10.7M |
| Diluted shares | 4.1M | 4.1M | 0.5M | 0.1M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $8.7M | $3.8M | $2.5M | $6.0M | $7.9M |
| Short-term investments | $8.4M | $23.0M | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $24.3M | $36.5M | $13.7M | $18.7M | $20.1M |
| Total liabilities | $8.1M | $10.7M | $7.6M | $7.3M | $5.6M |
| Shareholders' equity | $16.1M | $25.8M | $6.1M | $11.4M | $14.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology